Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2011-02-15
2011-02-15
Saoud, Christine J (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S145100, C530S387700, C530S387900, C530S388100
Reexamination Certificate
active
07887806
ABSTRACT:
Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.
REFERENCES:
patent: 5888774 (1999-03-01), Decluve
patent: 6495667 (2002-12-01), Bazan
patent: 6756481 (2004-06-01), Chirica et al.
patent: 7045595 (2006-05-01), Maeda et al.
patent: 7422743 (2008-09-01), Chirica et al.
patent: 7501247 (2009-03-01), Kastelein et al.
patent: 2003/0009018 (2003-01-01), Maeda et al.
patent: 2003/0082734 (2003-05-01), Dowling et al.
patent: 2004/0156849 (2004-08-01), Gurney
patent: 2004/0219150 (2004-11-01), Cua et al.
patent: 2005/0106673 (2005-05-01), Dowling et al.
patent: 1 221 482 (2002-07-01), None
patent: 1 221 482 (2005-12-01), None
patent: 273358 99 (1999-09-01), None
patent: WO 01/23556 (2000-09-01), None
patent: WO 00/73451 (2000-12-01), None
patent: WO 01/18051 (2001-03-01), None
patent: WO 01/85790 (2001-11-01), None
patent: WO 02/29060 (2002-04-01), None
U.S. Appl. No. 09/322,913, filed Jun. 1, 1999, Dowling et al.
U.S. Appl. No. 60/203,426, filed May 10, 2000, Chirica et al.
Aggarwal, S., et al.,J. Biol. Chem. 278(3):1910-1914, Jan. 17, 2003. “Interleukin-23 promotes a distinct CD4 T cell activation state characterized by production of interleukin-17”.
Barrett, Kim E., (Mar. 1996)Baillieres Clin. Gastroenterol. 10(1):1-15, “Cytokines: sources, receptors and signalling”.
Bazan, J. Fernando, et al.,Nature, 379:591, Feb. 15, 1996. “A newly defined interleukin-1?”.
Becker, Christoph, et al.,J. Clin. Invest. 112:693-706, Sep. 2003. “Constitutive p40 promoter activation and IL-23 production in the terminial ileum mediated by dendritic cells.”.
Birnbaum H.G. et al.: “Direct and indirect costs of asthma to an employer” Journal of Allergy and Clinical Immunology, vol. 109, No. 2, Feb. 2002, pp. 264-270.
Briscoe, J., et al.,Philos. Trans. R. Soc. Lond. B Biol. Sci. 351(1336):167-71, Feb. 29, 1996. “JAKs, STATs and signal transduction in response to the interferons and other cytokines”.
Chaiken and Williams (1996)Trends Biotechnol., 14(10):369-75, “Identifying structure-function relationships in four-helix bundle cytokines: towards de novo mimetics design”.
Cooper, Andrea M., et al., (2002)J. Immunol., 168:1322-1327, “Mice lacking bioactive IL-12 can generated protective, antigen-specific cellular responses to mycobacterial infection only if the IL-12 p40 subunit is present”.
Costabel U. and Guzman J.: “Bronchoalveolar lavage in interstitial lung disease” Current Opinion in Pulmonary Medicine, vol. 7, No. 5, 2001, pp. 255-261.
Cua, Daniel J., et al., (2003)Nature, 421:744-748, “Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain”.
Gately et al. (1998)Ann. Rev. Immunol. 16:495-521 “The Interleukin-12/Interleukin-12-Receptor System: Role in Normal and Pathologic Immune Responses”.
Gonda and D'Andrea, (1997)Blood89(2):355-369, “Activating mutations in cytokine receptors: implications for receptor function and role in disease”.
Gudmundsson G. et al.: “Viral infection modulates expression of hypersensitivity pneumonitis” Journal of Immunology, vol. 162, No. 12, 1999, pp. 7397-7401.
Happel, Kyle I., et al., (2003)J. Immunol., 170:4432-4436, “Cutting edge:roles of toll-like receptor 4 and IL-23 in IL-17 expression in response toKlebsiella pneumoniaeinfection”.
Heinrich, Peter C., et al., (1998)Biochem. J., 334 (Pt 2):297-314, “Interleukin 6-type cytokine signalling through the gp130/Jak/STAT pathway”.
Herz, Jeffrey M., et al., (1997)J. Recept. Signal Transduct. Res., 17(5):671-776, “Molecular approaches to receptors as targets for drug discovery”.
Hibi, M., et al., (Jan. 6, 1995)GenBank, Accession No. M57230, “Definition: Human membrane glycoprotein gp130 mRNA, complete cds.”.
Holscher, Christoph, et al., (2001)J. Immunol., 167:6957-6966, “A protective and agonistic function of IL-12p40 in mycobacterial infection”.
Iguchi Y. et al.: “Kimura's disease and its relation to angyolymphoid hyperplasia with eosinophilia: report of three cases and review of the literature” Journal of Oral Pathology, vol. 15, No. 3, 1986, pp. 132-137.
Ihle, James N., et al. (1997)Stem Cells, 15 (Suppl 1):105-11, “Jaks and Stats in cytokine signaling”.
Krajina, Tamara, et al., (2003)Eur. J. Immunol., 33:1073-1083, “Colonic lamina propria dendritic cells in mice with CD4+T cell-induced colitis”.
Levy, David E., (1997)Cytokine Growth Factor Rev., 8(1):81-90, “The house that JAK/STAT built”.
Lok, S., et al., (Sep. 19, 1999)Database EMBL Online!, Accession Number, AF178684, “Definition: Homo sapiens class I cytokine receptor (zcytor5) mRNA, complete cds”.
Mahairas, et al. (Aug. 1999)Proc. Natl. Acad. Sci. USA 96:9739-9744 “Sequence-tagged connectors: A sequence approach to mapping and scanning the human genome”.
http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=601604.
Ngo, et al. (1994)The Protein Folding Problem and Tertiary Structure Predictionpp. 491-495 “Computational complexity, protein structure prediction, and the Levinthal Paradox”.
Opalinska, et al. (2002)Nature Reviews Drug Discovery1:503-514 “Nucleic-acid therapeutics: basic principles and recent applications”.
Parham, Christi, et al.,J. Immunol. 168:5699-5708, 2002. “A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rb1 and a novel cytokine receptor subunit, IL-23R”.
Patel, Neela, et al., (1996)J. Biol. Chem., 271(48):30386-30391, “Functional replacement of cytokine receptor extracellular domains by leucine zippers”.
Pettit, et al. (1998)Trends in Biotech. 16:343-349 “The development of site-specific drug delivery systems for protein and peptide biopharmaceuticals”.
Phillips (2001)J. Pharmacy and Pharmacology53:1169-1174 “The challenge of gene therapy and DNA delivery”.
Presky, David H., et al., (1996)Proc. Natl. Acad. Sci. USA, 93:14002-14007, “A functional interleukin 12 receptor complex is composed of two b-type cytokine receptor subunits”.
Presky, David H., et al., (Nov. 28, 2000) GenBank, Accession No. U64198, “Definition: Human IL-12 receptor beta2 mRNA, complete cds.”.
Schuyler M. et al.: “Th1 cells that adoptively transfer experimental hypersensitivity pneumonitis are activated memory cells” Lung, vol. 177, No. 6, 1999, pp. 377-389.
Scott, et al. (Apr. 1999)Nature Genetics21:440-443 “The Pendred syndrome gene encodes a chloride-iodide transport protein”.
Shahar E. et al.: “Docosahexaenoic acid and smoking-related chronic obstructive pulmonary disease”. American Journal of Respiratory and Critical Care Medicine, vol. 159, No. 6, Jun. 1999, pp. 1780-1785.
Shahar E. et al.: “Dietary n-3 polyunsaturated fatty acids and smoking-related chronic obstructive pulmonary disease” New England Journal of Medicine, vol. 331, 1994, pp. 228-233.
Silvennoinen, Olli, et al, (1997)APMIS, 105(7):497-509, “Cytokine receptor signal transduction through Jak tyrosine kinases and Stat transcription factors”.
Smith P.J. et al.: “Suppression of granulocyte-macrophage colony-stimulating factor expression by glucocorticoids involves inhibition of enhancer function by the glucocorticoid receptor binding to composite NF-AT/Activator Protein-1 elements” Journal of Immunology, vol. 167, No. 5, 2001, pp. 2502-2510.
Tal A.: “Symbicort®: controlling asthma in children” Respiratory Medicine, vol. 96, No. Supplement A, Feb. 2002, pp. S23-S28.
Thien F.C.K. et al.: “Eicosanoids and asthma: an update”Prostaglandins Leukotrienes and Essential Fatty Acids, vol.
Chirica Madaline
Kastelein Robert A.
Moore Kevin
Parham Christi L.
Bellomy Gregory R.
Saoud Christine J
Schering Corporation
Seharaseyon Jegatheesan
LandOfFree
Mammalian receptor proteins DCRS5; method of treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mammalian receptor proteins DCRS5; method of treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mammalian receptor proteins DCRS5; method of treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2628169